Produktsname: | (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S, 6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl] oxy-6-(hydroxymethyl)oxane-3,5-diol |
CAS Registry Number: | 49842-07-1 |
EINECS: | 256-499-2 |
Synonyme: |
Nebicina; Tobramycin sulphate;sulfuric acid;(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S, 6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl] oxy-6-(hydroxymethyl)oxane-3,5-diol; Gernebcin; 1-Epitobramycin sulfate; Obracine; EINECS 256-499-2;TOBRAMYCIN SULFATE; Tobra; Tenemicin; Nebcin; |
Molecular Structure: | |
Molecular Formula: | C18H39N5O13S |
Molecular Weight: | 565.59296 |
Dichte: | 1.52g/cm3 |
Boiling Point: | 775.4°Cat760mmHg |
Flash Point: | 422.8°C |
Risiko-Codes: | 61-20/21/22 |
S-Sätze: | Poison by intravenous and intraperitoneal routes. Moderately toxic by subcutaneous route. Human systemic effects by intravenous route: wakefulness and hallucinations and distorted perceptions. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also TOBRAMYCIN and SULFATES. |
Gefahrensymbole: | T: Toxic; |